Open AccessEuropean Society of Cardiology / European Atherosclerosis Society 2019 Dyslipidemia Treatment Guideline: What Has Changed?
Author(s) -
Halil Doğrul,
Yusuf Çetin Doğaner,
Ümit Aydoğan
Publication year - 2020
Publication title -
eurasian journal of family medicine
Language(s) - English
Resource type - Journals
eISSN - 2147-3161
pISSN - 2147-3404
DOI - 10.33880/ejfm.2020090401
Subject(s) - dyslipidemia , guideline , medicine , mendelian randomization , cholesterol , randomized controlled trial , cardiology , atherosclerotic cardiovascular disease , ldl cholesterol , intensive care medicine , disease , pathology , biochemistry , chemistry , genetic variants , genotype , gene
After 3 years, European Society of Cardiology and the European Atherosclerosis Society published the new guideline for the management of dyslipidemias on August 2019. Comparing with the 2016 version, based on the latest prospective studies, randomized trials and Mendelian randomization studies, there are major changes in the recommendations; especially in the areas of total cardiovascular risk estimation, treatment targets and management of treatment, focusing on the combination therapy. Aforementioned studies indicated that it is possible to prevent atherosclerotic cardiovascular diseases by reducing low density lipoprotein cholesterol as early as and as much as possible since there is a correlation between the concentration of low density lipoprotein cholesterol in the blood and the risk of atherosclerotic cardiovascular diseases. In the light of those information the recommendation for patients at very high risk was changed as a low density lipoprotein cholesterol goal ofKeywords: dyslipidemia, guidelines, risk assessment, LDL cholesterol